Taken together, our data suggest that cetuximab can skew naïve monocytes toward an M1-polarized phenotype when co-cultured with EGFR+ tumor cells, including upregulation of M1 surface markers and cytokines and reduced M2 characteristics. Here, EGFR is linked to neoplasm.